A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma

Ocular Hypertension Clinical Trial

— DVX  

Official title:

A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00887029
• Other study ID #: OCC1023
• Status: Completed
• Phase: Phase 4
• First received: April 21, 2009
• Last updated: April 20, 2015
• Start date: January 2009
• Est. completion date: November 2009

Study information

• Verified date: April 2015
• Source: Ophthalmic Consultants Centres, Canada
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Hypothesis:

• H1: Efficacy of Duotrav will be superior to Xalacom at 24 hours post dosing when both medications are given in the morning

• H2: A significant proportion of patients will prefer dosing of once daily topical fixed combination therapy in the morning compared to evening dosing

Description:

• Primary objective: Compare IOP-lowering efficacy of morning dosing of Duotrav to Xalacom.

• Secondary objective: Compare patient dosing preferences for topical prostaglandin therapy in terms of convenience and perceived compliance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: November 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years old, diagnosed with primary open angle glaucoma or ocular hypertension

• IOP currently uncontrolled on beta blocker monotherapy, as judged by the investigator

• Response to Timolol 0.5% was a =10% reduction in IOP

• IOP at 9:00 of = 20 mmHg while still on beta blocker

• Non-prescription and prescription topical ophthalmic products and systemic medications other than those mentioned in the exclusion criteria will be allowed during the study.

• Patients wearing contact lenses will be permitted to participate in the study provided that the contact lenses are removed during instillation of study medication and that the patient waits fifteen (15) minutes following drug instillation to re-insert the lenses. Contact lenses cannot be worn on study days.

Exclusion Criteria:

• Best corrected visual acuity worse than 0.6 logMAR or 20/80 Snellen in either eye.

• Patients in whom the mean IOP in either eye at the screening exam visit is greater than 36 mmHg

• History of ocular trauma within the past six (6) months.

• History of ocular infection or ocular inflammation within the past three (3) months.

• History of chronic or recurrent severe inflammatory eye disease (i.e., scleritis, uveitis)

• History of severe or serious hypersensitivity to any components of the study medications.

• Any abnormality preventing reliable applanation tonometry of either eye.

• Intraocular surgery within the past six (6) months as determined by patient history and/or examination.

• Patients with cup/disc ratio greater than 0.80 in either eye.

• Patients with severe central visual field loss in either eye defined as a sensitivity 10 dB in at least two (2) of the four (4) visual field test points closest to the point of fixation.

• History of severe retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.

• Current use of ANY glucocorticoid administered by any route. Patient must have washed out of the glucocorticoid for at least 4 weeks prior to study entry.

• Use of any systemic prostaglandin or prostaglandin analogue (e.g., CYTOTEC) within the last three months.

• Current use of topical non-steroidal anti inflammatory agents which inhibit cyclo-oxygenase and prostaglandin analogue synthesis.

• Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component).

• Current use of topical non-steroidal anti inflammatory agents which inhibit cyclo-oxygenase and prostaglandin analogue synthesis

• Angle grade less than 2 (extreme narrow angle with complete or partial closure) as measured by gonioscopy.

• Therapy with another investigational agent within the past 30 days

• Patients who would be at risk from treatment with a topical prostaglandin or prostaglandin analogue, are contraindicated for use of beta-blockers or any other medication used in this study, or who would be at risk from participation in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Ocular Hypertension
• Open-Angle Glaucoma

Intervention

Drug:
• DuoTrav (travoprost-timolol ophthalmic drops)
topical ophthalmic drops instilled 1 drop daily
• Xalacom (latanoprost-timolol ophthalmic drops)
topical ophthalmic drops instilled 1 drop daily

Locations

Country	Name	City	State
Canada	Ophthalmic Consultant Centres	Mississauga	Ontario
Canada	Dr David B. Yan, M.D., F.R.C.S.C.	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Ophthalmic Consultants Centres, Canada	Alcon Research

Country where clinical trial is conducted

Canada, 

References & Publications (6)

Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743-52. — View Citation

Diestelhorst M, Larsson LI; European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocula — View Citation

Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated in — View Citation

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hyperten — View Citation

Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open- — View Citation

Yan DB, Battista RA, Haidich AB, Konstas AG. Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Curr Med Res Opin. 2008 Nov;24(11):3023-7. doi: 10.1185/030 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IOP lowering efficacy of DuoTrav and Xalacom		12 weeks	Yes
Secondary	To compare patient dosing preferences in terms of convenience and perceived compliance		12 weeks	No